KZIA vs NKTR

For growth investors, Nektar Therapeutics (NKTR) is the stronger pick with -43.

9% revenue growth year-over-year, versus -98. 2% for Kazia Therapeutics Limited (KZIA). Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -77.

6%, compared to -97. 3% for Kazia Therapeutics Limited (KZIA). Over 10 years, the gap is even starker: NKTR returned -73. 6% versus KZIA's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nektar Therapeutics (NKTR) is the lower-risk stock at 1.

50β versus Kazia Therapeutics Limited's 2. 06β — meaning KZIA is approximately 38% more volatile than NKTR relative to the S&P 500.

By revenue growth (latest reported year), Nektar Therapeutics (NKTR) is pulling ahead at -43.

9% versus -98. 2% for Kazia Therapeutics Limited (KZIA). On earnings-per-share growth, the picture is similar: Kazia Therapeutics Limited grew EPS 65. 6% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, KZIA leads at 61. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nektar Therapeutics (NKTR) is the more profitable company, earning -297.

1% net margin versus -492. 9% for Kazia Therapeutics Limited — meaning it keeps -297. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTR leads at -236. 8% versus -338. 5% for KZIA. At the gross margin level — before operating expenses — KZIA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nektar Therapeutics (NKTR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Kazia Therapeutics Limited (KZIA) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NKTR: -73. 6%, KZIA: -96. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.